Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T. Rosenstock J, et al. Among authors: hartman ml. Lancet. 2023 Aug 12;402(10401):529-544. doi: 10.1016/S0140-6736(23)01053-X. Epub 2023 Jun 26. Lancet. 2023. PMID: 37385280 Clinical Trial.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Retatrutide Phase 2 Obesity Trial Investigators. Jastreboff AM, et al. Among authors: hartman ml. N Engl J Med. 2023 Aug 10;389(6):514-526. doi: 10.1056/NEJMoa2301972. Epub 2023 Jun 26. N Engl J Med. 2023. PMID: 37366315 Clinical Trial.
Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures.
Vuppalanchi R, Loomba R, Sanyal AJ, Nikooie A, Tang Y, Robins DA, Brouwers B, Hartman ML. Vuppalanchi R, et al. Among authors: hartman ml. Aliment Pharmacol Ther. 2024 May 20. doi: 10.1111/apt.18042. Online ahead of print. Aliment Pharmacol Ther. 2024. PMID: 38768298
Incretin-based investigational therapies for the treatment of MASLD/MASH.
Brouwers B, Rao G, Tang Y, Rodríguez Á, Glass LC, Hartman ML. Brouwers B, et al. Among authors: hartman ml. Diabetes Res Clin Pract. 2024 May;211:111675. doi: 10.1016/j.diabres.2024.111675. Epub 2024 Apr 16. Diabetes Res Clin Pract. 2024. PMID: 38636848 Free article. Review.
Beverage consumption and obesity in Kuwaiti school children.
Alhareky M, Goodson JM, Tavares M, Hartman ML. Alhareky M, et al. Among authors: hartman ml. Front Endocrinol (Lausanne). 2024 Mar 11;14:1174299. doi: 10.3389/fendo.2023.1174299. eCollection 2023. Front Endocrinol (Lausanne). 2024. PMID: 38529102 Free PMC article.
124 results